{"id":"ct-p17-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Tuberculosis reactivation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P17 is a biosimilar of adalimumab (Humira), a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha, a key pro-inflammatory cytokine. By neutralizing TNF-alpha, the drug suppresses inflammatory immune responses in autoimmune and inflammatory conditions. The SC (subcutaneous) formulation allows for patient self-administration.","oneSentence":"CT-P17 SC is a subcutaneous formulation of a monoclonal antibody targeting TNF-alpha to reduce inflammatory cytokine signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:32.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT03789292","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-26","conditions":"Rheumatoid Arthritis","enrollment":648}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P17 SC","genericName":"CT-P17 SC","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"CT-P17 SC is a subcutaneous formulation of a monoclonal antibody targeting TNF-alpha to reduce inflammatory cytokine signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}